Specimen Instructions

FoundationOne CDx™ is a broad companion diagnostic (CDx) test for five tumor indications. In addition to use as a companion diagnostic, FICDx provides cancer relevant alterations that may inform patient management in accordance with professional guidelines. Information generated by this test is an aid in the identification of patients who are most likely to benefit from associated therapeutic products as noted in Table 1 of the Intended Use.¹

Acceptable Samples

- Formalin-fixed paraffin embedded (FFPE) specimens, including cut slide specimens are acceptable.
- Use standard fixation methods to preserve nucleic acid integrity. 10% neutral-buffered formalin for 6–72 hours is industry standard. DO NOT use other fixatives (Bouins, B5, AZF, Holland’s).
- Do not decalcify.

Sample Size

1. When feasible, please send the block + 1 H&E slide.*

   OR

2. 10 unstained slides (positively charged and unbaked at 4-5 microns thick) + 1 H&E slide.*

*For smaller samples, providing the original H&E will preserve material for testing.

Surface Area

3. MINIMUM: 25 mm²

   If sending slides, provide 10 unstained slides cut at 4-5 microns thick to achieve a tissue volume of 1 mm³.**

   **Specimens with a smaller surface area may meet volume requirements by submitting additional unstained slides (USS) or block.

Tumor Content

3. OPTIMUM: 30% TN  MINIMUM: 20% TN

   Percent tumor nuclei (%TN) = number of tumor cells divided by total number of all cells with nuclei

   Note for liver specimens: higher tumor content may be required because hepatocyte nuclei have twice the DNA content of other somatic nuclei

Shipping Instructions

1. Place the samples, FoundationOne CDx™ requisition form, insurance information, and any other attachments into the FoundationOne CDx Specimen Shipping Kit.

2. Place the specimen shipping kit (including samples and paperwork) into the provided FedEx shipping pack, first ensuring that primary specimen containers (e.g. blocks, slides) are labeled with two patient-specific identifiers. Seal the shipping pack.

3. Complete the pre-printed shipping labels (if necessary) and apply to shipping pack.

4. Call 800.463.3339 to request a pick-up or drop the package at your site’s designated FedEx pick-up location and ship sealed shipping pack to:

   Foundation Medicine, Inc.
   150 Second Street
   Cambridge, MA 02141
   Phone: 888.988.3639
Intended Use

FoundationOne CDx™ (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The F1CDx assay is a single-site assay performed at Foundation Medicine, Inc.

Table 1: Companion diagnostic indications

<table>
<thead>
<tr>
<th>INDICATIONS</th>
<th>BIOMARKER</th>
<th>FDA-APPROVED THERAPY*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>EGFR exon 19 deletions and EGFR exon 21 L858R alterations</td>
<td>Gilotrif® (afatinib), Iressa® (gefitinib), or Tarceva® (erlotinib)</td>
</tr>
<tr>
<td></td>
<td>EGFR exon 20 T790M alterations</td>
<td>Tagrisso® (osimertinib)</td>
</tr>
<tr>
<td></td>
<td>ALK rearrangements</td>
<td>Alecensa® (alectinib), Xalkori® (crizotinib), or Zykadia® (ceritinib)</td>
</tr>
<tr>
<td></td>
<td>BRAF V600E</td>
<td>Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>BRAF V600E</td>
<td>Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)</td>
</tr>
<tr>
<td></td>
<td>BRAF V600E or V600K</td>
<td>Mekinist® (trametinib) or Cotellic® (cobimetinib), in combination with Zelboraf® (vemurafenib)</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>ERBB2 (HER2) amplification</td>
<td>Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)</td>
</tr>
<tr>
<td>Colorectal Cancer</td>
<td>KRAS wild-type (absence of mutations in codons 12 and 13)</td>
<td>Erbitux® (cetuximab)</td>
</tr>
<tr>
<td></td>
<td>KRAS wild-type (absence of mutations in exons 2, 3 and 4) and NRAS wild-type (absence of mutations in exons 2, 3 and 4)</td>
<td>Vectibix® (panitumumab)</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>BRCA1/2 alterations</td>
<td>Rubraca® (rucaparib)</td>
</tr>
</tbody>
</table>

Reference

1. For full information on the intended use, assay descriptions, and for detailed performance specifications, refer to the complete FoundationOne CDx label at www.foundationmedicine.com/F1cdx.

* Tarceva® is the registered trademark of OSI Pharmaceuticals, LLC. Zelboraf®, Herceptin®, Perjeta®, Kadcyla®, and Cotellic® are registered trademarks of Genentech, Inc. Gilotrif® is a registered trademark of Boehringer Ingelheim International GmbH. Iressa® and Tagrisso® are registered trademarks of the AstraZeneca group of companies. Xalkori® is a registered trademark of Pfizer Inc. Zykadia®, Tafinlar®, and Mekinist® are registered trademarks of Novartis AG Corporation Switzerland. Erbitux® is a registered trademark of ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company. Alecensa® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha. Vectibix® is a registered trademark of Immunex Corporation. Rubraca® is a registered trademark of Clovis Oncology, Inc.